GS-9716 + Anticancer Therapies for Advanced Solid Cancers
Trial Summary
What is the purpose of this trial?
This trial is testing a new cancer drug called GS-9716 in patients with advanced solid cancers. The goal is to find the highest safe dose and see if it causes any serious side effects, both alone and with other treatments.
Will I have to stop taking my current medications?
The trial requires a 'washout period' (time without taking certain medications) for prior systemic anti-cancer therapy, but it does not specify about other medications. You may need to discuss your current medications with the trial team to see if any adjustments are necessary.
What data supports the effectiveness of the drug GS-9716 combined with other anticancer therapies for advanced solid cancers?
What makes the drug GS-9716 unique for treating advanced solid cancers?
GS-9716, also known as zamzetoclax, is unique because it is being studied in combination with other anticancer therapies for advanced solid cancers, potentially offering a novel approach compared to existing treatments. While the specific mechanism of action for GS-9716 is not detailed in the provided research, its combination with other therapies suggests it may enhance treatment effectiveness or reduce side effects.13678
Eligibility Criteria
Adults with advanced solid tumors who have tried at least one standard treatment or for whom no standard treatment is suitable. They must be in fairly good physical condition (ECOG status of 0 or 1), have a certain level of heart, kidney, and liver function, and cannot have untreated brain metastases or serious health conditions like active hepatitis B/C or autoimmune diseases.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive escalating doses of zamzetoclax as monotherapy or in combination with other anti-cancer agents to determine the maximum tolerated dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- Docetaxel (Chemotherapy)
- Gemcitabine (Chemotherapy)
- GS-9716 (Other)
- Sacituzumab Govitecan-hziy (Monoclonal Antibodies)